Sharemaestro company-news research for BioMarin Pharmaceutical Inc. (B1MR34), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
SAO
Brazil
Provisional evidence
Company news sentiment
Latest B1MR34 news and sentiment
BioMarin Pharmaceutical Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
20/100 evidence confidence
78% direct company focus
13 current stories across 3 publishers
Current company news
Early balanced news score
13 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone63/100
→
Published 30-day score51/100
Latest source headline
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?
finance.yahoo.com · 19 Sep 2026 14:12
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
13 current stories are mapped specifically to B1MR34.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.102.
Confidence is 20/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
78%/100
Company news13 company stories
96/100
Story agreement4/100 difference
News history
Daily score and story count over 30 days
23 Aug07 Sep21 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.102 after freshness weightingSource breadth60
3 independent publishersCompany relevance78
share tied directly to this companyFreshness35
recency-weighted evidenceAgreement96
how closely stories agreePublisher mix43
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202651BRL 168.800003+1.7%
11 Sep 202651BRL 166.039993-3.1%
04 Sep 202653BRL 171.350006+2.1%
28 Aug 202655BRL 167.789993-2.0%
21 Aug 202659BRL 171.190002+0.5%
14 Aug 202661BRL 170.369995+5.8%
07 Aug 202663BRL 161.100006+8.3%
31 Jul 202650BRL 148.800003+0.0%
Provisional evidence
News subjects
What is shaping the score
Earnings526 stories · 46%
Market update504 stories · 31%
Regulatory and legal602 stories · 15%
Deals and strategy501 stories · 8%
Source mix
Where the evidence comes from
PR Newswire544 stories · 31%
finance.yahoo.com504 stories · 31%
Insider Monkey652 stories · 15%
Zacks571 stories · 8%
Benzinga551 stories · 8%
GlobeNewswire501 stories · 8%
Recurring subjects
Subjects appearing most often
Biotech10Royalties6Pharma5Fda Approval4M A3Revenue Growth2Rare Diseases2Patent Dispute2Healthcare2Fourth Quarter2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral21 Sep 17:46
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 21 Sep 17:46 | 51 | +0 | 19/100 (-1) | 13 (-1) | Provisional |
| 19 Sep 23:59 | 51 | +0 | 20/100 (-1) | 14 (0) | Provisional |
| 18 Sep 23:59 | 51 | -1 | 21/100 (-2) | 14 (-6) | Provisional |
| 16 Sep 23:59 | 52 | +0 | 23/100 (-2) | 20 (-1) | Provisional |
| 14 Sep 23:59 | 52 | -1 | 25/100 (-3) | 21 (-1) | Provisional |
| 12 Sep 23:59 | 53 | +1 | 28/100 (+4) | 22 (-5) | Provisional |
| 09 Sep 23:59 | 52 | -1 | 24/100 (0) | 27 (-7) | Provisional |
| 04 Sep 23:59 | 53 | +0 | 24/100 (-1) | 34 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
finance.yahoo.comDirect company coverageStored article
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite interest around VOXZOGO data and the fresh board-level scientific expertise. Capitalize on the renewed focus
Balance SheetRare DiseasesRevenue GrowthRevenue GrowthShare PriceShareholder
- Published
- 19 Sep 2026 14:12
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.1d old
- Duplicates
- 1 consolidated
#2—Not directional
finance.yahoo.comDirect company coverageStored article
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. Amicus integration is advancing: BioMarin expects $200 million in annual non-GAAP cost savings, with most synergies realized in 2027 and full realization in 2028. The deal is expected to accelerate deleveraging, with leverage falling below 2.5 times by mid-2027. VOXZOGO is nearing blockbuster status: The drug delivered 20% quarterly patient growth despite U.S. competition, and BioMarin expects revenue to reach approximately $1 billion this year. Potential approval in hypochondroplasia could provide addi
BiotechEarningsHealthcareM AQuarterly ResultsRare Diseases
- Published
- 18 Sep 2026 17:02
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.0d old
- Duplicates
- 1 consolidated
#3—Not directional
finance.yahoo.comDirect company coverageStored article
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical BMRN announced that it is discontinuing the development of Voxzogo (vosoritide) for children with Noonan syndrome, a rare genetic condition that can affect growth and development in multiple parts of the body. This announcement came via an SEC filing on Tuesday, which attributed the decision to the study's feasibility and the current treatment landscape. The company clarified that the decision was not related to the safety or efficacy of Voxzogo. In March, BioMarin ended development of the drug for three other short stature indications, Turner Syndrome, SHOX-deficiency
BiotechFda ApprovalRoyalties
- Published
- 16 Sep 2026 16:01
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.1d old
- Duplicates
- 1 consolidated
#4—Not directional
PR NewswireDirect company coverageStored article
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.BioMarin Pharmaceutical logo Dr. Plenge is Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, where he leads the organization's scientific work across nine research sites worldwide. He joined Bristol Myers Squibb in November 2019 as part of its acquisition of Celgene Corp., where he served as vice president of the immunology
BiotechBoard Appointment
- Published
- 14 Sep 2026 13:05
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.2d old
- Duplicates
- 1 consolidated
#565Tone
Insider MonkeyDirect company coverageStored article
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis's achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International Trade Commission, which BioMarin has agreed to drop as part of the settlement. Ascendis reiterated the same terms in its own announcement the following day, calling the arrangement a binding term
BiotechInstitutional InvestorsRoyaltiesSettlementSplit
- Published
- 12 Sep 2026 17:02
- News subject
- Regulatory and legal
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 49/100
- 30-day weight
- 72.7% of the score · 9.0d old
- Duplicates
- 1 consolidated
#657Tone
PR NewswireDirect company coverageStored article
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswir
BiotechClinical TrialsFda ApprovalPharma
- Published
- 09 Sep 2026 13:05
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 17.9% of the score · 12.2d old
- Duplicates
- 1 consolidated
#7—Not directional
Insider MonkeyDirect company coverageStored article
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net sales, retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea through May 2030. The settlement resolves proceedings before the U.S. International Tra
CompetitionHealthcarePatent SettlementPharmaRoyalties
- Published
- 04 Sep 2026 16:26
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.1d old
- Duplicates
- 1 consolidated
#857Tone
ZacksDirect company coverageStored article
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
For BioMarin Pharmaceutical BMRN, the FDA approval of Ascendis Pharma's ASND Yuviwel in February had created a problem — a new entrant targeting the same achondroplasia market as Voxzogo, its key revenue driver. But a recent settlement between the two companies has changed the economics of that competition in a meaningful way. Rather than continue fighting a competitor that had already entered the market, BioMarin has found a way to make the competitor pay it. Under the settlement, Ascendis will pay BioMarin royalties on Yuviwel sales in the United States, European Union, Brazil and South Kore
BiotechFda ApprovalPatent DisputePharmaRoyalties
- Published
- 03 Sep 2026 16:28
- News subject
- Earnings
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 9.5% of the score · 18.1d old
- Duplicates
- 1 consolidated
#9—Not directional
PR NewswireDirect company coverageStored article
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.BioMarin Pharmaceutical logo An audio webcast of the presentation will be available live. You can access th
BiotechConferences
- Published
- 02 Sep 2026 13:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.2d old
- Duplicates
- 1 consolidated
#10—Not directional
PR NewswireDirect company coverageStored article
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin's skeletal conditions portfolio, adding ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. ALE1 is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing
BiotechM APharma
- Published
- 01 Sep 2026 13:05
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.2d old
- Duplicates
- 1 consolidated
#11—Not directional
BenzingaDirect company coverageStored article
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S(NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma's Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-weekly treatment for children with achondroplasia. Read Also:BioMarin Seeks to Strengthen Market Positi
Fda ApprovalFourth QuarterPatent DisputePharmaceuticalsRevenueRoyalties
- Published
- 31 Aug 2026 12:06
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.2d old
- Duplicates
- 1 consolidated
#12—Not directional
GlobeNewswireDirect company coverageStored article
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Ascendis Pharma COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. ("BioMarin") related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies. Under the terms, BioMarin has agreed to grant Ascendis a non-exclusive, worldwide, royalty-bearing license, allowing Ascendis
BiotechFourth QuarterM ARegulation
- Published
- 31 Aug 2026 11:00
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.3d old
- Duplicates
- 1 consolidated
#13—Not directional
finance.yahoo.comDirect company coverageStored article
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in th
BiotechPatent AgreementPharmaRoyalties
- Published
- 31 Aug 2026 06:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.5d old
- Duplicates
- 1 consolidated
Earlier company news
B1MR34 news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 32 older B1MR34 headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to B1MR34, but the headline and available text are not mainly about BioMarin Pharmaceutical Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of B1MR34 sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.